Precipio Inc
$ 26.52
-1.16%
05 Mar - close price
- Market Cap 31,614,300 USD
- Current Price $ 26.52
- High / Low $ 27.00 / 25.63
- Stock P/E N/A
- Book Value 8.10
- EPS -1.19
- Next Earning Report 2026-03-26
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.09 %
- ROE -0.15 %
- 52 Week High 28.50
- 52 Week Low 3.90
About
Precipio, Inc., a cancer diagnostic and reagent technology company, provides diagnostic products and services in the United States oncology market. The company is headquartered in New Haven, Connecticut.
Analyst Target Price
$19.00
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-14 | 2025-08-13 | 2025-05-12 | 2025-03-31 | 2024-11-11 | 2024-08-13 | 2024-05-14 | 2023-11-13 | 2023-08-11 | 2023-05-12 | 2023-03-30 | 2022-11-10 |
| Reported EPS | -0.05 | 0.05 | -0.5883 | -0.2444 | -0.4229 | -0.8336 | 0.6514 | -1.04 | -0.09 | -0.13 | -0.1 | -0.14 |
| Estimated EPS | None | None | None | 0.74 | None | None | None | -1.21 | -0.1 | -0.13 | -0.14 | -0.04 |
| Surprise | 0 | 0 | 0 | -0.9844 | 0 | 0 | 0 | 0.17 | 0.01 | 0 | 0.04 | -0.1 |
| Surprise Percentage | None% | None% | None% | -133.027% | None% | None% | None% | 14.0496% | 10% | 0% | 28.5714% | -250% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-26 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: PRPO
2026-03-01 17:22:00
This article analyzes Precipio Inc. (NASDAQ: PRPO), detailing a weak near-term sentiment that could precede shifts in its mid and long-term outlook. It identifies a significant 49.9:1 risk-reward setup, targeting a 15.3% gain with only 0.3% risk. The analysis also provides three AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—tailored for different risk profiles and holding periods, along with multi-timeframe signal analysis and support/resistance levels.
2026-02-27 21:51:47
Precipio, Inc. (NASDAQ: PRPO) announced preliminary unaudited financials for Q4 and full-year 2025, reporting a significant turnaround to profitability and positive cash flow. Revenues grew 30% year-over-year to $24.0 million in 2025, with Q4-2025 showing net income of $0.5 million and positive operating cash flow of $0.4 million. The company achieved positive adjusted EBITDA of $0.95 million in Q4-2025 and $1.23 million for the full year, marking a key milestone for future growth projects.
2026-02-27 04:52:12
Precipio (NASDAQ: PRPO) announced preliminary unaudited financial results for 2025, reporting a significant 30% year-over-year revenue increase to $24.0 million. The company achieved positive Adjusted EBITDA of $1.23 million and positive operating cash flow of $688,000 for the full year, marking a turn towards profitability. Precipio's CEO, Ilan Danieli, highlighted the importance of becoming cash-flow positive, allowing for long-term growth investments.
2026-02-26 02:40:46
Precipio, a blood cancer diagnostics firm, announced a preliminary 23% increase in its fourth-quarter revenue. This short report, distributed by Reuters, highlights the company's Q4 financial performance.
2026-02-25 14:52:46
Precipio, Inc. announced preliminary financial results for Q4 and fiscal year 2025, showing significant revenue growth of 30% year-over-year, reaching $24 million. The company achieved positive Adjusted EBITDA of $0.95 million for Q4 and $1.23 million for the full year, a substantial improvement from previous losses. Additionally, Precipio reported positive operating cash flow of $368,000 for Q4 and $688,000 for the full year, indicating improved financial health and operational efficiency.
2026-02-25 14:52:46
Precipio, Inc. announced preliminary unaudited financial results for fiscal year 2025, reporting a 30% year-over-year revenue increase to $24.0M. The company also achieved positive Adjusted EBITDA of $1.23M for the full year and positive operating cash flow of $688K. This marks a significant shift, enabling investment in growth projects rather than focusing on short-term cash burn.
